I think it is a reasonable prediction that this current blackout period could be related to a sale of the company in progress. The reasons include:
-having an interim CEO for close to 10 months who has a deal-making background (if they planned to stay independent they would have made him permanent or hired a permanent one by now, considering the negative impact that the uncertainty has had on the stock)
-program delays, including the submission of the EU application as well as the start of and amendment to the NEO trial (which could be related to "negotiations" with a buyer such as Amgen)
-Majority of the senior management team disappeared from the company's listing of their management team in material, and CFO wrote odd article promoting her value to clinical stage biotechs that in no way benefited ADXS but would benefit her in a job search
-IR not responding to calls about what happened to the missing key executives, and also not responding to any calls period, even calls from long-term investors with good relationships with IR
-Accumulated poor management of the company, driven from O'Connor's liberal and self-serving spending and unfocused business strategy, have exhausted investor goodwill and confidence, as evidenced by the company forced to sell a 20% stake for an all time low price to maintain "a years worth of cash"
-Any selling of another 20% stake for a record low stock price, now under $2, would obliterate shareholder value even more, making the most sensible option to sell the company now (unless management proves to be completely self-serving, but I don't think this is the case because that is why O'Connor was replaced)
-Patients will benefit from a sale of the company to put the platform in stronger hands and get the life saving treatments to the market faster
